$0.65
0.62% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US74365N1037
Symbol
PTIX

Protagenic Therapeutics Inc Stock price

$0.65
+0.03 5.38% 1M
-0.91 58.59% 6M
-0.34 34.75% YTD
-0.15 19.25% 1Y
-6.63 91.13% 3Y
-7.35 91.93% 5Y
-166.37 99.61% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.62%
ISIN
US74365N1037
Symbol
PTIX

Key metrics

Market capitalization $4.39m
Enterprise Value $3.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.32
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-5.27m
Free Cash Flow (TTM) Free Cash Flow $-4.64m
Cash position $1.06m
EPS (TTM) EPS $-1.27
Short interest 2.52%
Show more

Is Protagenic Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Protagenic Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Protagenic Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Protagenic Therapeutics Inc:

Buy
100%

Financial data from Protagenic Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
-
-
-0.06 -0.06
-
-
- Selling and Administrative Expenses 1.09 1.09
22% 22%
-
- Research and Development Expense 4.05 4.05
58% 58%
-
-5.21 -5.21
31% 31%
-
- Depreciation and Amortization 0.06 0.06
-
-
EBIT (Operating Income) EBIT -5.27 -5.27
33% 33%
-
Net Profit -5.65 -5.65
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protagenic Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagenic Therapeutics Inc Stock News

Neutral
Accesswire
21 days ago
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of...
Neutral
Accesswire
28 days ago
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stoc...

Company Profile

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Head office United States
Employees 3
Founded 1994
Website www.protagenic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today